PMID- 15046750
OWN - NLM
STAT- MEDLINE
DCOM- 20041126
LR  - 20151119
IS  - 0956-5663 (Print)
IS  - 0956-5663 (Linking)
VI  - 19
IP  - 10
DP  - 2004 May 15
TI  - Simultaneous detection of C-reactive protein and other cardiac markers in human 
      plasma using micromosaic immunoassays and self-regulating microfluidic networks.
PG  - 1193-202
AB  - We show a proof-of-concept in which we combine our previously published concepts 
      of micromosaic immunoassays (microMIAs) with self-regulating microfluidic 
      networks (microFNs) to detect C-reactive protein (CRP) and other cardiac markers 
      such as myoglobin (Mb) and cardiac Troponin I (cTnI). The microFNs are 
      microfabricated in Si, have a well-defined surface chemistry, and are affixed to 
      a bibulous material so as to self-regulate the displacement of an aliquot of 
      liquid through the microFNs using capillary forces. An open section of the 
      channels of the microFNs is covered with a hydrophobic poly(dimethylsiloxane) 
      (PDMS) slab that acts as the substrate for a solid-phase immunoassay. Here, 
      individual assays are conducted using independent channels. These assays are 
      "sequential": series of samples, reagents, and buffers are displaced one after 
      the other over the PDMS surface, and, as these assays are conducted under 
      "microfluidic" conditions, they are fast to perform, very economical in their use 
      of reagents, extremely integrated, and yield high-quality signals. The 
      combinatorial character of microMIAs is exploited to optimize the assay 
      parameters for detecting CRP. In particular, we found it optimal to deposit the 
      capture antibody for CRP on PDMS at a concentration between 20 and 500 microg 
      ml(-1) in PBS in 1 min and to detect captured CRP in 2 min using a detection 
      antibody having a concentration in PBS of 120 microg ml(-1). With this method, 
      CRP is quantitatively detected within 10 min in one microliter of human plasma 
      down to concentrations of 30 ng ml(-1), which suggests the possibility to detect 
      CRP at clinically relevant concentrations for the management of coronary heart 
      disease (CHD) and systemic inflammation.
FAU - Wolf, Marc
AU  - Wolf M
AD  - IBM Research, Zurich Research Laboratory, IBM Research, Saumerstrasse 4/Posfach, 
      CH-8803 Ruschlikon, Switzerland.
FAU - Juncker, David
AU  - Juncker D
FAU - Michel, Bruno
AU  - Michel B
FAU - Hunziker, Patrick
AU  - Hunziker P
FAU - Delamarche, Emmanuel
AU  - Delamarche E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Biosens Bioelectron
JT  - Biosensors & bioelectronics
JID - 9001289
RN  - 0 (Antibodies)
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Antibodies/immunology
MH  - Biomarkers
MH  - Biosensing Techniques/*methods
MH  - C-Reactive Protein/*analysis/immunology/metabolism
MH  - Humans
MH  - Immunoassay/methods
MH  - Kinetics
MH  - Microfluidics/methods
MH  - Myocardium/*metabolism
EDAT- 2004/03/30 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/03/30 05:00
PHST- 2003/06/25 00:00 [received]
PHST- 2003/10/21 00:00 [revised]
PHST- 2003/11/13 00:00 [accepted]
PHST- 2004/03/30 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/03/30 05:00 [entrez]
AID - S0956566303003993 [pii]
AID - 10.1016/j.bios.2003.11.003 [doi]
PST - ppublish
SO  - Biosens Bioelectron. 2004 May 15;19(10):1193-202. doi: 
      10.1016/j.bios.2003.11.003.